ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
-5.04%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$497M
AUM Growth
+$497M
(+36%)
Cap. Flow
+$71.1M
Cap. Flow
% of AUM
14.31%
Top 10 Holdings %
Top 10 Hldgs %
61.21%
Holding
306
New
59
Increased
87
Reduced
47
Closed
53
Top Buys
| 1 |
Cytokinetics
CYTK
|
$29M |
| 2 |
Protagonist Therapeutics
PTGX
|
$28.4M |
| 3 |
BridgeBio Pharma
BBIO
|
$18.1M |
| 4 |
Roivant Sciences
ROIV
|
$14.4M |
| 5 |
Royalty Pharma
RPRX
|
$12.1M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$43.3M |
| 2 |
MACK
Merrimack Pharmaceuticals, Inc.
MACK
|
$13.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
$4.21M |
| 4 |
EDR
Endeavor Group Holdings, Inc.
EDR
|
$3.91M |
| 5 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$3.78M |
Sector Composition
| 1 | Healthcare | 85.86% |
| 2 | Financials | 1.87% |
| 3 | Industrials | 0.23% |
| 4 | Utilities | 0.18% |
| 5 | Materials | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
CytomX Therapeutics
CTMX
$350M
| $698K | 0.13% |
572,170
+417,170
| +269% | +$509K |
|
77
Perspective Therapeutics
CATX
$251M
| $698K | 0.13% |
69,985
-606,740
| -90% | +$23.1K |
|
|
CLYM
78
Climb Bio, Inc. Common Stock
CLYM
$165M
| $695K | 0.13% |
+97,695
| New | +$695K |
|
79
Beyond Air
XAIR
$12.1M
| $658K | 0.12% |
1,225,270
+20,450
| +2% | +$11K |
|
80
Kezar Life Sciences
KZR
$28.5M
| $652K | 0.12% |
1,086,498
+849,875
| +359% | +$510K |
|
|
VXRT
81
DELISTED
Vaxart
VXRT
| $631K | 0.12% |
+945,568
| New | +$631K |
|
82
Corteva
CTVA
$49.2B
| $615K | 0.12% |
11,400
-26,000
| -70% | -$1.4M |
|
|
ARYD
83
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
| $614K | 0.12% |
53,527
+12,597
| +31% | +$144K |
|
84
Akero Therapeutics
AKRO
$3.65B
| $598K | 0.11% |
25,507
+23,700
| +1,312% | +$556K |
|
85
Taysha Gene Therapies
TSHA
$791M
| $562K | 0.11% |
250,800
+207,300
| +477% | +$464K |
|
86
Actinium Pharmaceuticals
ATNM
$53.3M
| $556K | 0.11% |
75,133
-24,867
| -25% | -$184K |
|
|
TMTC
87
DELISTED
TMT Acquisition Corp Ordinary Shares
TMTC
| $549K | 0.1% |
50,000
| – | – |
|
88
Corbus Pharmaceuticals
CRBP
$121M
| $543K | 0.1% |
12,000
-4,000
| -25% | -$181K |
|
89
Rhythm Pharmaceuticals
RYTM
$6.75B
| $534K | 0.1% |
13,000
+600
| +5% | +$24.6K |
|
90
Ardelyx
ARDX
$1.57B
| $519K | 0.1% |
+70,000
| New | +$519K |
|
91
AB Ultra Short Income ETF
YEAR
$1.51B
| $505K | 0.1% |
10,000
| – | – |
|
92
PGIM Ultra Short Bond ETF
PULS
$12.3B
| $497K | 0.09% |
10,000
| – | – |
|
93
Stevanato
STVN
$6.36B
| $495K | 0.09% |
27,000
+11,500
| +74% | +$211K |
|
94
Day One Biopharmaceuticals
DAWN
$766M
| $484K | 0.09% |
+35,100
| New | +$484K |
|
95
Gossamer Bio
GOSS
$587M
| $480K | 0.09% |
532,628
-200,000
| -27% | -$180K |
|
96
Abeona Therapeutics
ABEO
$356M
| $480K | 0.09% |
+113,125
| New | +$480K |
|
|
97
Alnylam Pharmaceuticals
ALNY
$58.6B
| $450K | 0.08% |
1,850
-178,295
| -99% | -$43.3M |
|
98
PolyPid
PYPD
$54.4M
| $447K | 0.08% |
+103,950
| New | +$447K |
|
99
Sanofi
SNY
$122B
| $442K | 0.08% |
9,100
+3,600
| +65% | +$175K |
|
100
TherapeuticsMD
TXMD
$12.7M
| $435K | 0.08% |
270,160
-2,000
| -0.7% | -$3.22K |
|